Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050921 · ClinicalTrials.gov registry record · NA
Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00050921: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00050921 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050921, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.
Interventions
- DRUG somatropin
- BIOLOGICAL Hepatitis A virus, inactivated
- DRUG Keyhole-Limpet Hemocyanin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Est. Completion | 2005-03 |
| Phase | NA |
What the finished NCT00050921 record still lists
NCT00050921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which somatropin is the first listed.
NCT00050921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050921 about?
NCT00050921 is a clinical study titled "Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs". This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.
What is the current status of trial NCT00050921?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00050921?
The interventions under investigation include: somatropin (DRUG), Hepatitis A virus, inactivated (BIOLOGICAL), Keyhole-Limpet Hemocyanin (DRUG).
Who is sponsoring clinical trial NCT00050921?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00050921's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors